Noordenbos J, Doré C, Hansbrough JF, et al.
The Journal of burn care & rehabilitation. Date of publication 1999 Jul 1;volume 20(4):275-81.
1. J Burn Care Rehabil. 1999 Jul-Aug;20(4):275-81.
Safety and efficacy of TransCyte for the treatment of partial-thickness burns.
Noordenbos J(1), Doré C, Hansbrough JF.
Author information:
(1)Department of Surgery, University of California, San Diego Medical Center
92103, USA.
Standard treatment for extensive partial-thickness burns in the United States and
in much of the world involves the application of topical antimicrobial agents and
repetitive wound débridements and dressing changes. We evaluated a new biologic
wound covering, TransCyte (Advanced Tissue Sciences, La Jolla, Calif, formerly
marketed as Dermagraft-Transitional Covering), for the treatment of
partial-thickness burns. This material is composed of human newborn fibroblasts
which are then cultured on the nylon mesh of Biobrane (Dow B. Hickam, Inc,
Sugarland, Tex); the thin silicone membrane bonded to the mesh provides a
moisture vapor barrier for the wound. A prospective, randomized, comparison study
of silver sulfadiazine and TransCyte was performed with the use of paired wound
sites on 14 patients. Wounds treated with TransCyte healed more quickly (mean
11.14 days to 90% epithelialization vs 18.14 days, P = .002). A noncomparison
evaluation was then done for an additional 18 patients, and it confirmed
excellent wound healing and an absence of infections. There were no infections in
the 32 wound sites treated with TransCyte. In the first study group, late wound
evaluations (3, 6, and 12 months postburn) were performed with use of the
Vancouver Scar Scale. The results indicated that wound sites treated with
TransCyte healed with less hypertrophic scarring than sites treated with silver
sulfadiazine (P < .001 at 3 and 6 months, P = .006 at 12 months).
PMID: 10425589 [Indexed for MEDLINE]
